Becton Dickinson and Co (NYSE:BDX) reported earnings of $2.91 per share beating Walls Streets expectations.

ME Staff
-
0

Becton Dickinson and Co (NYSE:BDX) reported Q3 2018 earnings this Morning, coming in at $2.91 per share, beating Wall Street’s estimates of $2.86 per Share. Revenue for the quarter came in at $4.28 billion beating analyst estimates of $4.25 billion



    Dividend History for Becton Dickinson and Co (NYSE:BDX)

    • On 7/24/2018 Becton Dickinson and Co announced a quarterly dividend of $0.75 1.21% with an ex dividend date of 9/6/2018 which will be payable on 9/7/2018.
    • On 4/23/2018 Becton Dickinson and Co announced a quarterly dividend of $0.75 1.29% with an ex dividend date of 6/7/2018 which will be payable on 6/8/2018.
    • On 1/22/2018 Becton Dickinson and Co announced a quarterly dividend of $0.75 1.38% with an ex dividend date of 3/8/2018 which will be payable on 3/9/2018.
    • On 11/20/2017 Becton Dickinson and Co announced a quarterly dividend of $0.75 1.32% with an ex dividend date of 12/7/2017 which will be payable on 12/8/2017.
    • On 7/25/2017 Becton Dickinson and Co announced a quarterly dividend of $0.73 1.44% with an ex dividend date of 9/7/2017 which will be payable on 9/8/2017.
    • On 5/23/2017 Becton Dickinson and Co announced a quarterly dividend of $0.73 1.56% with an ex dividend date of 6/7/2017 which will be payable on 6/9/2017.
    • On 1/23/2017 Becton Dickinson and Co announced a quarterly dividend of $0.73 1.71% with an ex dividend date of 3/8/2017 which will be payable on 3/10/2017.



    About Company
    Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

    Recent Analyst Rating for Becton Dickinson and Co (NYSE:BDX)

    • On 7/24/2018 quarterly, $0.75, to 1.21% with a price target of 9/6/2018
    • On 9/7/2018 9/28/2018 4/23/2018, quarterly, to $0.75 with a price target of 1.29%
    • On 6/7/2018 6/8/2018, 6/29/2018 1/22/2018, to quarterly with a price target of $0.75
    • On 3/8/2018 3/9/2018, 3/30/2018 11/20/2017, to quarterly with a price target of $0.75
    • On 12/7/2017 12/8/2017, 12/29/2017 7/25/2017, to quarterly with a price target of $0.73
    • On 9/7/2017 9/8/2017, 9/29/2017 5/23/2017, to quarterly with a price target of $0.73



    Recent Trading for Becton Dickinson and Co (NYSE:BDX)
    Shares of Becton Dickinson and Co closed the previous trading session at 245.10 −4.90 1.96% with shares trading hands.